Pfizer launches phase III trial with RSV candidate in September
Following positive data from a phase IIa trial, Pfizer is ready to launch a phase III trial with adults next month with the vaccine candidate rsvpref for treating respiratory syncytial virus (RSV).
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Following positive data from a phase IIa trial, US pharmaceutical company Pfizer is ready to initiate another phase III trial with the vaccine candidate RSVpreF fo treating respiratory syncytial virus (RSV), according to Fiercebiotech.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer and Moderna raise prices for coronavirus vaccines
For subscribers
Sanofi to establish mRNA vaccine center with 400 employees
For subscribers
